SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hugo J. A. Adams, Thomas C. Kwee, Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis, Annals of Hematology, 2016, 95, 5, 695

    CrossRef

  2. 2
    Massimo Martino, Moreno Festuccia, Roberta Fedele, Giuseppe Console, Michele Cimminiello, Paolo Gavarotti, Benedetto Bruno, Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents, Expert Opinion on Biological Therapy, 2016, 16, 3, 347

    CrossRef

  3. 3
    Chen Wang, Panli Li, Shan Wu, Jianda Lu, Qiufang Liu, Huajie Luo, Shaoli Song, The role of fluorine-18 fluorodeoxyglucose PET in prognosis evaluation for stem cell transplantation of lymphoma, Nuclear Medicine Communications, 2016, 37, 4, 338

    CrossRef

  4. 4
    Charlotte Mellier, Franck Fayon, Florian Boukhechba, Elise Verron, Myriam LeFerrec, Gilles Montavon, Julie Lesoeur, Verena Schnitzler, Dominique Massiot, Pascal Janvier, Olivier Gauthier, Jean-Michel Bouler, Bruno Bujoli, Design and properties of novel gallium-doped injectable apatitic cements, Acta Biomaterialia, 2015, 24, 322

    CrossRef

  5. 5
    Oscar B. Lahoud, Craig S. Sauter, Paul A. Hamlin, Parastoo Bahrami Dahi, High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma, Current Oncology Reports, 2015, 17, 9

    CrossRef

  6. 6
    Alison J Moskowitz, Heiko Schöder, Joachim Yahalom, Susan J McCall, Stephanie Y Fox, John Gerecitano, Ravinder Grewal, Paul A Hamlin, Steven Horwitz, Rachel Kobos, Anita Kumar, Matthew Matasar, Ariela Noy, M Lia Palomba, Miguel-Angel Perales, Carol S Portlock, Craig Sauter, Neerav Shukla, Peter Steinherz, David Straus, Tanya Trippett, Anas Younes, Andrew Zelenetz, Craig H Moskowitz, PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study, The Lancet Oncology, 2015, 16, 3, 284

    CrossRef

  7. 7
    Gary A. Ulaner, Debra A. Goldman, Craig S. Sauter, Jocelyn Migliacci, Joshua Lilienstein, Mithat Gönen, Heiko Schöder, Craig H. Moskowitz, Andrew D. Zelenetz, Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma, Radiology, 2015, 277, 2, 518

    CrossRef

  8. 8
    Graham P. Collins, Anne N. Parker, Christopher Pocock, Irfan Kayani, Anna Sureda, Tim Illidge, Kirit Ardeshna, David C. Linch, Karl S. Peggs, Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma, British Journal of Haematology, 2014, 164, 1
  9. 9
    M A Kharfan-Dabaja, M Hamadani, H Sibai, B N Savani, Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!, Bone Marrow Transplantation, 2014, 49, 5, 599

    CrossRef

  10. 10
    Francesca Montanari, Catherine Diefenbach, Relapsed Hodgkin Lymphoma: Management Strategies, Current Hematologic Malignancy Reports, 2014, 9, 3, 284

    CrossRef

  11. 11
    Mark Hertzberg, Relapsed/Refractory Hodgkin Lymphoma, Hematology/Oncology Clinics of North America, 2014, 28, 1, 123

    CrossRef

  12. 12
    K J Thomson, I Kayani, K Ardeshna, E C Morris, R Hough, A Virchis, A H Goldstone, D C Linch, K S Peggs, A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma, Leukemia, 2013, 27, 6, 1419

    CrossRef

  13. 13
    Yago Nieto, Uday Popat, Paolo Anderlini, Ben Valdez, Borje Andersson, Ping Liu, Chitra Hosing, Elizabeth J. Shpall, Amin Alousi, Partow Kebriaei, Muzaffar Qazilbash, Simrit Parmar, Qaiser Bashir, Nina Shah, Issa Khouri, Gabriela Rondon, Richard Champlin, Roy B. Jones, Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome, Biology of Blood and Marrow Transplantation, 2013, 19, 3, 410

    CrossRef

  14. 14
    Luciano Wannesson, Mario Bargetzi, Anne Cairoli, Alessandra Cerutti, Dominik Heim, Urs Hess, Erika Lerch, Thomas Pabst, Christoph Renner, Panagiotis Samaras, Emanuele Zucca, Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone), Leukemia & Lymphoma, 2013, 54, 1, 36

    CrossRef

  15. 15
    Regine Kluge, Lars Kurch, Françoise Montravers, Christine Mauz-Körholz, FDG PET/CT in children and adolescents with lymphoma, Pediatric Radiology, 2013, 43, 4, 406

    CrossRef

  16. 16
    Tiziana Moscato, Roberta Fedele, Giuseppe Messina, Giuseppe Irrera, Giuseppe Console, Massimo Martino, Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma, Expert Opinion on Biological Therapy, 2013, 13, 7, 1013

    CrossRef

  17. 17
    A V MARTIN, D CUNNINGHAM, B SHARMA, Positron emission tomography/CT in the management of lymphoma, Imaging, 2013, 22, 1, 20110086

    CrossRef

  18. 18
    S Akhtar, A S Al-Sugair, M Abouzied, Y AlKadhi, M Dingle, M Abdelsalam, H Soudy, A Darwish, A Eltigani, T A M Elhassan, M Nabil-Ahmed, I Maghfoor, Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT, Bone Marrow Transplantation, 2013, 48, 12, 1530

    CrossRef

  19. 19
    Anna Czyz, Anna Lojko-Dankowska, Dominik Dytfeld, Adam Nowicki, Lidia Gil, Magdalena Matuszak, Maria Kozlowska-Skrzypczak, Maciej Kazmierczak, Ewa Bembnista, Mieczysław Komarnicki, Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience, Medical Oncology, 2013, 30, 3

    CrossRef

  20. 20
    Christof Scheid, Allogeneic stem cell transplantation or novel agents for the treatment of relapsed/refractory Hodgkin’s lymphoma?, International Journal of Hematologic Oncology, 2012, 1, 2, 103

    CrossRef

  21. 21
    Sally Moore, Irfan Kayani, Karl Peggs, Wendi Qian, Lisa Lowry, Kirsty Thomson, David C. Linch, Kirit Ardeshna, Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL, British Journal of Haematology, 2012, 157, 5
  22. 22
    Stephanie A. Terezakis, Yvette L. Kasamon, Tailored strategies for radiation therapy in classical Hodgkin's lymphoma, Critical Reviews in Oncology/Hematology, 2012, 84, 1, 71

    CrossRef

  23. 23
    Bastian von Tresckow, Andreas Engert, The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplant, Expert Review of Hematology, 2012, 5, 5, 483

    CrossRef

  24. 24
    Esa Jantunen, Anna Sureda, The Evolving Role of Stem Cell Transplants in Lymphomas, Biology of Blood and Marrow Transplantation, 2012, 18, 5, 660

    CrossRef

  25. 25
    Anna Sureda, Maria I. Barbosa Pereira, Peter Dreger, The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkinʼs lymphoma, Current Opinion in Oncology, 2012, 24, 6, 727

    CrossRef

  26. 26
    John W. Sweetenham, “Pet Negativity”—The New Goal of Cytoreductive Therapy in Hodgkin's Lymphoma?, Biology of Blood and Marrow Transplantation, 2011, 17, 11, 1569

    CrossRef

  27. 27
    Paolo Corradini, Barbara Sarina, Lucia Farina, Allogeneic transplantation for Hodgkin’s lymphoma, British Journal of Haematology, 2011, 152, 3
  28. 28
    Gülsan Türköz Sucak, Zübeyde Nur Özkurt, Elif Suyanı, Demet Gökalp Yaşar, Özgür Ümit Akdemir, Zeynep Akı, Zeynep Arzu Yeğin, Münci Yağcı, Özlem Lütfiye Kapucu, Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival, Annals of Hematology, 2011, 90, 11, 1329

    CrossRef

  29. 29
    J. Kuruvilla, A. Keating, M. Crump, How I treat relapsed and refractory Hodgkin lymphoma, Blood, 2011, 117, 16, 4208

    CrossRef

  30. 30
    Heidi Mocikova, Robert Pytlik, Jana Markova, Katerina Steinerova, Zdenek Kral, David Belada, Marie Trnkova, Marek Trneny, Vladimir Koza, Jiri Mayer, Pavel Zak, Tomas Kozak, Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma, Leukemia & Lymphoma, 2011, 52, 9, 1668

    CrossRef

  31. 31
    Martin Hutchings, Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients?, Leukemia & Lymphoma, 2011, 52, 9, 1615

    CrossRef

  32. 32
    Jacob P. Smeltzer, Amanda F. Cashen, Qin Zhang, Andrew Homb, Farrokh Dehdashti, Camille N. Abboud, John F. DiPersio, Keith E. Stockerl-Goldstein, Geoffrey L. Uy, Ravi Vij, Peter Westervelt, Nancy L. Bartlett, Todd A. Fehniger, Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, 2011, 17, 11, 1646

    CrossRef

  33. 33
    Yvette L. Kasamon, Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography, Advances in Hematology, 2011, 2011, 1

    CrossRef

  34. 34
    Bastian von Tresckow, Andreas Engert, The Role of Autologous Transplantation in Hodgkin Lymphoma, Current Hematologic Malignancy Reports, 2011, 6, 3, 172

    CrossRef

  35. 35
    Rachel B. Salit, Michael R. Bishop, Steven Z. Pavletic, Allogeneic Hematopoietic Stem Cell Transplantation: Does It Have a Place in Treating Hodgkin Lymphoma?, Current Hematologic Malignancy Reports, 2010, 5, 4, 229

    CrossRef

  36. 36
    Masahiro Okada, Norihide Sato, Kazunari Ishii, Kaname Matsumura, Makoto Hosono, Takamichi Murakami, FDG PET/CT versus CT, MR Imaging, and67Ga Scintigraphy in the Posttherapy Evaluation of Malignant Lymphoma1, RadioGraphics, 2010, 30, 4, 939

    CrossRef

  37. 37
    Craig H. Moskowitz, Joachim Yahalom, Andrew D. Zelenetz, Zhigang Zhang, Daniel Filippa, Julie Teruya-Feldstein, Tarun Kewalramani, Alison J. Moskowitz, Robert David Rice, Jocelyn Maragulia, Jill Vanak, Tanya Trippett, Paul Hamlin, Steven Horowitz, Ariela Noy, Owen A. O’Connor, Carol Portlock, David Straus, Stephen D. Nimer, High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging, British Journal of Haematology, 2010, 148, 6
  38. 38
    Bharti Rathore, Marshall E Kadin, Hodgkin's lymphoma therapy: past, present, and future, Expert Opinion on Pharmacotherapy, 2010, 11, 17, 2891

    CrossRef

  39. 39
    Sally Arai, Renee Letsinger, Ruby M. Wong, Laura J. Johnston, Ginna G. Laport, Robert Lowsky, David B. Miklos, Judith A. Shizuru, Wen-Kai Weng, Philip W. Lavori, Karl G. Blume, Robert S. Negrin, Sandra J. Horning, Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma, Biology of Blood and Marrow Transplantation, 2010, 16, 8, 1145

    CrossRef

  40. 40
    Anna Dodero, Roberto Crocchiolo, Francesca Patriarca, Rosalba Miceli, Luca Castagna, Fabio Ciceri, Stefania Bramanti, Niccolo Frungillo, Raffaella Milani, Flavio Crippa, Federico Fallanca, Emanuela Englaro, Paolo Corradini, Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation, Cancer, 2010, 116, 21
  41. 41
    A. J. Moskowitz, J. Yahalom, T. Kewalramani, J. C. Maragulia, J. M. Vanak, A. D. Zelenetz, C. H. Moskowitz, Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma, Blood, 2010, 116, 23, 4934

    CrossRef

  42. 42
    Loukia S. Poulou, Loukas Thanos, Panayiotis D. Ziakas, Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials, European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1, 156

    CrossRef

  43. 43
    Luca Castagna, Barbara Sarina, Elisabetta Todisco, Massimo Magagnoli, Monica Balzarotti, Stefania Bramanti, Rita Mazza, Antonella Anastasia, Andrea Bacigalupo, Franco Aversa, Davide Soligo, Laura Giordano, Armando Santoro, Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma, Biology of Blood and Marrow Transplantation, 2009, 15, 4, 432

    CrossRef

  44. 44
    Luca Castagna, Stefania Bramanti, Monica Balzarotti, Barbara Sarina, Elisabetta Todisco, Antonella Anastasia, Massimo Magagnoli, Rita Mazza, Andrea Nozza, Laura Giordano, Marcello Rodari, Eva Rinifilo, Arturo Chiti, Armando Santoro, Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy, British Journal of Haematology, 2009, 145, 3
  45. 45
    Sandra Horning, Textbook of Medical Oncology, Fourth Edition, 2009,

    CrossRef

  46. 46
    Ginna G. Laport, Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review, Leukemia & Lymphoma, 2008, 49, 10, 1854

    CrossRef

  47. 47
    Karl S. Peggs, Paolo Anderlini, Anna Sureda, Allogeneic transplantation for Hodgkin lymphoma, British Journal of Haematology, 2008, 143, 4
  48. You have free access to this content48
    Current Awareness in Hematological Oncology, Hematological Oncology, 2008, 26, 1
  49. 49
    Yvette L Kasamon, Richard L Wahl, FDG PET and risk-adapted therapy in Hodgkinʼs and non-Hodgkinʼs lymphoma, Current Opinion in Oncology, 2008, 20, 2, 206

    CrossRef

  50. 50
    Panayiotis D. Ziakas, Loukia S. Poulou, Improving outcome after positive interim PET in advanced Hodgkin’s disease: reality vs expectation, European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 8, 1573

    CrossRef

  51. 51
    Nancy L Bartlett, Modern treatment of Hodgkin lymphoma, Current Opinion in Hematology, 2008, 15, 4, 408

    CrossRef

  52. 52
    A V Martin, B Sharma, Positron emission tomography and CT in the management of lymphoma, Imaging, 2008, 20, 3, 169

    CrossRef

  53. 53
    Roberto Crocchiolo, Carla Canevari, Andrea Assanelli, Francesca Lunghi, Michela Tassara, Maria Lupo Stanghellini, Daniela Clerici, Claudio Landoni, Paolo Servida, Massimo Bernardi, Jacopo Peccatori, Andres Ferreri, Luigi Gianolli, Claudio Bordignon, Federico Caligaris-Cappio, Fabio Ciceri, Ferruccio Fazio, Pre-transplant18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation, Leukemia & Lymphoma, 2008, 49, 4, 727

    CrossRef

  54. 54
    Ignacio G. Escobar, Pilar T. Alonso, Dolores C. Barrigon, Jose A. Perez-Simon, Maria V. Mateos Manteca, Jesus F. San Miguel Izquierdo, Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation, Annals of Nuclear Medicine, 2008, 22, 4, 251

    CrossRef

  55. 55
    Kevin A. David, Lauren Mauro, Andrew M. Evens, Relapsed and Refractory Hodgkin Lymphoma: Transplantation Strategies and Novel Therapeutic Options, Current Treatment Options in Oncology, 2007, 8, 5, 352

    CrossRef

  56. 56
    Philip J. Bierman, Auayporn Nademanee, Hematopoietic Cell Transplantation for Hodgkin Disease,
  57. 57
    Eva Domingo-Domenech, Anna Sureda, Hodgkin lymphoma,
  58. 58
    Michael Crump, Hodgkin Lymphoma,
  59. 59
    Parastoo Bahrami Dahi, Gabriela Soriano Hobbs, Miguel-Angel Perales, Use of transplantation in lymphoma,